Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 9, 2009, Pages 928-937

  Metz, D C ^b   Vakily, M ^a,c   Dixit, T ^c   Mulford, D ^c  

^a TAKEDA PHARMACEUTICALS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; DEXLANSOPRAZOLE MR; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SCH 298080; TAK 390MR; UNCLASSIFIED DRUG; VB 101; VECAM;

CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; HUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 63849151475     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03984.x     Document Type: Review

References (50)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 100 : 190 200.
2. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001 15 : 355 70.
3. Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease - what are the unmet clinical needs? Aliment Pharmacol Ther 2006 23 (suppl 2 9 22.
4. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005 22 : 79 94.
5. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005 22 (suppl 3 10 9.
6. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998 10 : 119 24.
7. Feldman M. Gastric Secretion. In Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 8th edn. Philadelphia, PA : Saunders Elsevier, 2006.
8. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995 35 : 277 305.
9. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006 23 (suppl 2 2 8.
10. Sachs G, Shin J, Vagin O, Lambrecht N, Yakubov I, Munson K. The Gastric H, K ATPase of a Drug Target: past, present, and future. J Clin Gastroenterol 2007 41 (Suppl 2 S226 42.
11. Tonini M, DeGiorgio R, DePonti F. Novel therapeutic strategies in acid-related disorders. Expert Opin Ther Patents 2003 13 : 639 49.
12. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000 6 (9 Suppl S491 505.
13. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005 100 : 1949 56.
14. Metz DC, Ferron GM, Paul J, et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. J Clin Pharmacol 2002 42 : 512 9.
15. Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005 22 (Suppl 3 20 4.
16. Yacyshyn BR, Thomson AB. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002 66 : 67 78.
17. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000 14 : 963 78.
18. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000 14 : 1595 603.
19. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988 95 : 903 12.
20. Bate CM, Booth SN, Crowe JP, Hepworth-Jones B, Taylor MD, Richardson PD. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993 7 : 501 7.
21. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996 91 : 1532 8.
22. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 23 : 1296 310.
23. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003 25 : 2307 35 discussion 2306.
24. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997 20 : 1512 7.
25. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000 28 : 966 72.
26. Miner P, Katz P, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 98 : 2616 20.
27. Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis 2006 24 : 11 46.
28. Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y. Effects of TU-199, a novel H+, K+-ATPase inhibitor, on gastric acid secretion and gastoduodenal ulcers in rats. Methods Find Exp Clin Pharmacol 1999 21 : 115 22.
29. Goldwater R, Lee S, Chung G, Kim D, Cho K, Boileau F. A phase I, randomized, parallel placebo-controlled safety, tolerance and pharmacokinetic study of multiple doses of IY-8119 in fasting male volunteers (abstract). Clin Pharmacol Ther 1999 65 : 126.
30. Periclou AP, Goldwater R, Lee SM, et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther 2000 68 : 304 11.
31. Datamonitor. Pipeline insight: upper GI disorders. Report No.: DMHC2312. Available from: http://www.datamonitor.com (accessed 15 November 2007).
32. Vecta Ltd. Company profile. 2008 http://www.vecta.co.il/about.html. Accessed April 10.
33. Howden CW. Review article: immediate-release proton-pump inhibitor therapy - potential advantages. Aliment Pharmacol Ther 2005 22 (Suppl 3 25 30.
34. Hunt RH, Armstrong D, Yaghoob M, et al. Predicable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008 28 : 187 99.
35. Hunt RH, Armstrong D, Yaghoobi M, et al. Inhibition of acid secretion by a novel proton pump inhibitor (abstract). Gastroenterology 2007 132 (suppl 2 A486.
36. Katsuki H, Yagi H, Arimori K, et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res 1996 13 : 611 5.
37. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 14 : 861 7.
38. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000 14 : 1249 58.
39. Zhang W, Wu J, Atkinson S. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology 2007 132 (suppl 52 A487 (abstract).
40. Vakily M, Zhang W, Wu J, Atkinson S, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009 25 : 627 38.
41. Vakily M, Wu JT, Atkinson S, Mulford D. Population pharmacokinetics (PK) of TAK-390MR in subjects with symptomatic non-erosive gastroesophageal reflux disease (GERD). J Clin Pharmacol 2008 48 : 1103 (abstract).
42. Mayer MD, Vakily M, Witt G, Mulford DJ. The pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis. Gastroenterology 2008 134 (4 suppl 1 A176 (abstract).
43. Dabholkar A, Yu P, Paris M. Long-Term Safety of TAK-390MR, a PPI with a Novel Dual Delayed Release Formulation, in GERD Patients. Am J Gastroenterol 2008 103 (Suppl 1 S5 6 (abstract).
44. Metz DC, Howden CW, Perez MC, Larsen LM, O'Neil J, Atkinson SN. Clinical Trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed release technology, effectively controls symptoms and prevents relapse in patients with healed erosive esophagitis. Aliment Pharmacol Ther 2009 29 : 742 54.
45. Sharma P, Shaheen NJ, Perez MC, et al. Healing of erosive esophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: Results from 2 randomized controlled trials. Aliment Pharmacol Ther 2009 29 : 731 41.
46. Howden CW, Larsen L, Palmer R, Perez MC. Placebo-Controlled trial of 2 doses of TAK-390MR, a PPI with novel dual delayed release technology, as maintenance treatment for patients with healed erosive esophagitis (EE). Am J Gastroenterol 2008 103 (suppl 1 S5 (abstract).
47. Bell NJV, Burger D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992 51 : 59 67.
48. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974 19 : 716 23.
49. Wu J, Vakily M, Witt G, Mulford D. TAK-390MR vs. lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%-time pH>4. Am J Gastroenterol 2007 102 (suppl 2 S124 (abstract).
50. Howden CW, Jones DB, Peace KE, Burget DW, Hunt RH. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig Dis Sci 1988 33 : 619 24.